NiKang Therapeutics Competitors and Similar CompaniesClear all
NiKang Therapeutics's competitors and similar companies include StemMed, Tvardi Therapeutics, Telix Pharmaceuticals and Plus Therapeutics.
 NiKang Therapeutics NiKang Therapeutics is a biotech company focused on developing small molecule oncology medicines. |  StemMed StemMed is a pharmaceutical development and testing company that provides pre-clinical drug testing services using a panel of patient-derived xenograft (PDX) models of breast and pancreatic cancers. |  Tvardi Therapeutics Tvardi Therapeutics is a biotechnology company developing medicines for the treatment of cancer, chronic inflammation, and fibrosis. |  Telix Pharmaceuticals Telix Pharmaceuticals is a company developing molecularly targeted radiation products for cancer care. |  Plus Therapeutics Plus Therapeutics is a pharmaceutical company focused on the development of treatments for patients battling cancer and other life-threatening diseases. | |
Founding Date | Founding Date 2017 | Founding Date 2009 | Founding Date 2017 | Founding Date 2015 | Founding Date 1996 |
Type | Type Private | Type Private | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Wilmington, US HQ | Locations Houston, US HQ | Locations Houston, US HQ Houston, US | Locations Austin, US HQ San Antonio, US | |
Employees | Employees 403% increase | Employees 2 | Employees 19 | Employees 415 | Employees 1721% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 4.6 b | Valuation ($) 8 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $803.8m (FY, 2025) | Revenue (est.) $5.2m (FY, 2025) |
Net income | Net income N/A | Net income N/A | Net income N/A | Net income ($7.1m) (FY, 2025) | Net income ($22.4m) (FY, 2025) |
Funding | |||||
Latest funding round | Latest funding round $ 200m (almost 5 years ago) | Latest funding round N/A | Latest funding round $ 74m (almost 5 years ago) | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised $ 200m | Total funding raised N/A | Total funding raised $ 88m | Total funding raised N/A | Total funding raised $ 71.9m |
For sources of this data, please see the company profile
View Company Profiles
StemMed
HQ
Houston, US
Employees
2
StemMed is a pharmaceutical development and testing company that provides pre-clinical drug testing services using a panel of patient-derived xenograft (PDX) models of breast and pancreatic cancers.
View companyTvardi Therapeutics
HQ
Houston, US
Employees
19
Tvardi Therapeutics is a biotechnology company developing medicines for the treatment of cancer, chronic inflammation, and fibrosis.
View companyTelix Pharmaceuticals
HQ
North Melbourne, AU
Employees
415
Telix Pharmaceuticals is a company developing molecularly targeted radiation products for cancer care.
View companyPlus Therapeutics
HQ
Austin, US
Employees
17↑ 21% increase
Plus Therapeutics is a pharmaceutical company focused on the development of treatments for patients battling cancer and other life-threatening diseases.
View company